Eyam Vaccines and Immunotherapeutics
Eyam Vaccines and Immunotherapeutics is a private Canadian company dedicated to the research and development of safe, efficacious, and low-dose vaccines. Named after the historic village in Derbyshire known for its selfless quarantine during the plague, the company aims to create sterilizing vaccines that halt infection and transmission of COVID-19 and its variants. Eyam is actively advancing preclinical and clinical trials, including efforts to develop pan-coronavirus vaccines capable of addressing current and future variants such as Omicron. The company leverages proprietary platforms like self-amplifying mRNA and collaborates with institutions like the University of British Columbia to innovate in vaccine technology. Eyam also focuses on next-generation vaccine technologies and has appointed new board members and scientific advisors to support its mission.
Industries
Nr. of Employees
small (1-50)
Eyam Vaccines and Immunotherapeutics
Products
Computational antigen design platform
A bioinformatics platform combining machine learning and standardized genomics workflows to prioritize antigen and epitope targets for multi-antigen vaccine and immunotherapeutic design, with support for variant integration.
Self-amplifying nucleic-acid delivery platform
A vector architecture engineered to function as self-amplifying RNA or DNA, designed for large multi-epitope payloads, with formulation approaches to improve thermal stability and delivery options that may avoid lipid-nanoparticle dependency.
Gemini
A versatile genetic instruction delivery platform that spans therapeutic antibodies, enzymes, cytokines, and vaccine antigens across infectious disease, oncology, autoimmune, and rare disease.
Gemini-D
Self-amplifying DNA (saDNA) therapeutic platform delivering 6+ month expression from a single dose with integration below FDA limits.
Gemini-R
Self-amplifying RNA (saRNA) vaccine and therapeutic platform providing approximately 42-day expression with zero genomic integration.
Gemini self-amplifying DNA
Self-amplifying DNA (saDNA) platform that expresses therapeutic proteins or antibodies in the body from a single, thermostable, carrier-optional dose.
Computational antigen design platform
A bioinformatics platform combining machine learning and standardized genomics workflows to prioritize antigen and epitope targets for multi-antigen vaccine and immunotherapeutic design, with support for variant integration.
Self-amplifying nucleic-acid delivery platform
A vector architecture engineered to function as self-amplifying RNA or DNA, designed for large multi-epitope payloads, with formulation approaches to improve thermal stability and delivery options that may avoid lipid-nanoparticle dependency.
Gemini
A versatile genetic instruction delivery platform that spans therapeutic antibodies, enzymes, cytokines, and vaccine antigens across infectious disease, oncology, autoimmune, and rare disease.
Gemini-D
Self-amplifying DNA (saDNA) therapeutic platform delivering 6+ month expression from a single dose with integration below FDA limits.
Gemini-R
Self-amplifying RNA (saRNA) vaccine and therapeutic platform providing approximately 42-day expression with zero genomic integration.
Gemini self-amplifying DNA
Self-amplifying DNA (saDNA) platform that expresses therapeutic proteins or antibodies in the body from a single, thermostable, carrier-optional dose.
Services
Establishment and management of collaborative R&D projects and licensing agreements with academic and industry partners to advance platform vaccine and therapeutic candidates, including commercial licensing that can include manufacturing and distribution rights.
Design and execution support for preclinical study programs, including animal-model testing and integration with computational design outputs to evaluate candidate immunogenicity and efficacy.
Coordination and program management services to support transition from preclinical studies into clinical trial activities and to manage clinical trial operations.
Establishment and management of collaborative R&D projects and licensing agreements with academic and industry partners to advance platform vaccine and therapeutic candidates, including commercial licensing that can include manufacturing and distribution rights.
Design and execution support for preclinical study programs, including animal-model testing and integration with computational design outputs to evaluate candidate immunogenicity and efficacy.
Coordination and program management services to support transition from preclinical studies into clinical trial activities and to manage clinical trial operations.
Expertise Areas
- Vaccine platform research and development
- Computational antigen and epitope design
- Next-generation sequencing analysis and bioinformatics
- Self-amplifying nucleic-acid vaccine platforms
Key Technologies
- Self-amplifying nucleic-acid platforms (RNA/DNA)
- Next-generation sequencing (NGS) analysis pipelines
- Machine learning for antigen and epitope prediction
- High-performance computing for bioinformatics
News & Updates
Eyam Vaccines and Immunotherapeutics (EYAM) announced the licensing agreement with UBC to develop proprietary COVID-19 vaccine candidates in a self-amplifying mRNA platform, aiming to address the urgent societal need for effective vaccines against SARS-CoV-2 variants.
Eyam announced the commencement of preclinical studies to evaluate the efficacy of vaccine candidates targeting SARS-CoV-2 variants, including Omicron, utilizing their proprietary self-amplifying mRNA platform developed in collaboration with UBC.
Dr. Reno Pontarollo, President & COO of EYAM, emphasizes the company's goal to develop sterilizing vaccines that can effectively halt COVID-19 infection and transmission, including efforts to incorporate Omicron sequencing into their pan-coronavirus vaccine development.
Dr. Ribeca, an expert in genomics and bioinformatics, joins EYAM’s Scientific Advisory Board to enhance vaccine design and development, leveraging his expertise in high-throughput sequencing data analysis.
Eyam is actively updating its vaccine candidates to include Omicron variant sequencing, aiming to develop more robust vaccines capable of preventing infection and transmission of current and future SARS-CoV-2 variants.
Eyam's Gemini platform aims to revolutionize biologics manufacturing and distribution on a global scale.
Eyam Vaccines and Immunotherapeutics (EYAM) announced the licensing agreement with UBC to develop proprietary COVID-19 vaccine candidates in a self-amplifying mRNA platform, aiming to address the urgent societal need for effective vaccines against SARS-CoV-2 variants.
Eyam announced the commencement of preclinical studies to evaluate the efficacy of vaccine candidates targeting SARS-CoV-2 variants, including Omicron, utilizing their proprietary self-amplifying mRNA platform developed in collaboration with UBC.
Dr. Reno Pontarollo, President & COO of EYAM, emphasizes the company's goal to develop sterilizing vaccines that can effectively halt COVID-19 infection and transmission, including efforts to incorporate Omicron sequencing into their pan-coronavirus vaccine development.
Dr. Ribeca, an expert in genomics and bioinformatics, joins EYAM’s Scientific Advisory Board to enhance vaccine design and development, leveraging his expertise in high-throughput sequencing data analysis.
Eyam is actively updating its vaccine candidates to include Omicron variant sequencing, aiming to develop more robust vaccines capable of preventing infection and transmission of current and future SARS-CoV-2 variants.
Eyam's Gemini platform aims to revolutionize biologics manufacturing and distribution on a global scale.